<- Go Home
Verici Dx plc
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Market Cap
GBP 20.5M
Volume
292.1K
Cash and Equivalents
GBP 2.6M
EBITDA
-GBP 7.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 1.0M
Profit Margin
100.00%
52 Week High
GBP 0.17
52 Week Low
GBP 0.07
Dividend
N/A
Price / Book Value
4.04
Price / Earnings
-1.65
Price / Tangible Book Value
9.80
Enterprise Value
GBP 18.4M
Enterprise Value / EBITDA
-2.42
Operating Income
-GBP 8.4M
Return on Equity
115.94%
Return on Assets
-48.36
Cash and Short Term Investments
GBP 2.6M
Debt
GBP 540.0K
Equity
GBP 3.6M
Revenue
GBP 1.0M
Unlevered FCF
-GBP 3.8M
Sector
Biotechnology
Category
N/A